View ValuationLabGenomics 将来の成長Future 基準チェック /06現在、 LabGenomicsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長24.5%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesNew Risk • Jun 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 70% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (₩85.9b market cap, or US$56.3m).お知らせ • May 22LabGenomics Co., Ltd. announced that it has received KRW 20 billion in fundingOn May 20, 2026, LabGenomics Co., Ltd. has closed the transaction.お知らせ • May 13LabGenomics Co., Ltd. announced that it expects to receive KRW 20 billion in fundingLabGenomics Co., Ltd. announces a private placement with Stick Litmus Co., Ltd. to issue Series 5 Unregistered Unsecured Private Convertible Bonds for gross proceeds of KRW 20,000,000,000 on May 12, 2026. Expected closing date of the transaction is May 20, 2026. Interest rate of the Notes is 0% and Maturity interest rate is 5%. Maturity date of the Notes is May 20, 2029. Notes are convertible into 13,642,564 shares at a conversion price of KRW 1,466. Conversion billing period starts from May 20, 2027 and ends on April 20, 2029.お知らせ • Feb 28LabGenomics Co., Ltd., Annual General Meeting, Mar 31, 2026LabGenomics Co., Ltd., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: auditorium, 700, daewangpangyo-ro, bundang-gu, gyeonggi-do, seongnam South Korea分析記事 • Jan 28Little Excitement Around LabGenomics Co., Ltd.'s (KOSDAQ:084650) RevenuesYou may think that with a price-to-sales (or "P/S") ratio of 1.5x LabGenomics Co., Ltd. ( KOSDAQ:084650 ) is definitely...New Risk • Dec 15New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩141.1b (US$96.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 57% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩141.1b market cap, or US$96.4m).分析記事 • Oct 28LabGenomics Co., Ltd.'s (KOSDAQ:084650) Price Is Right But Growth Is LackingWith a price-to-sales (or "P/S") ratio of 2.1x LabGenomics Co., Ltd. ( KOSDAQ:084650 ) may be sending very bullish...New Risk • May 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 30% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (10% average weekly change).分析記事 • May 19Insufficient Growth At LabGenomics Co., Ltd. (KOSDAQ:084650) Hampers Share PriceLabGenomics Co., Ltd.'s ( KOSDAQ:084650 ) price-to-sales (or "P/S") ratio of 2.2x might make it look like a strong buy...分析記事 • Apr 08Is LabGenomics (KOSDAQ:084650) Using Debt In A Risky Way?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...お知らせ • Feb 21LabGenomics Co., Ltd., Annual General Meeting, Mar 26, 2025LabGenomics Co., Ltd., Annual General Meeting, Mar 26, 2025, at 09:00 Tokyo Standard Time. Location: auditorium, 700, daewangpangyo-ro, bundang-gu, gyeonggi-do, seongnam South KoreaNew Risk • Jan 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 25% per year over the past 5 years.分析記事 • Jan 06There's No Escaping LabGenomics Co., Ltd.'s (KOSDAQ:084650) Muted Revenues Despite A 46% Share Price RiseLabGenomics Co., Ltd. ( KOSDAQ:084650 ) shareholders would be excited to see that the share price has had a great...分析記事 • Nov 17Not Many Are Piling Into LabGenomics Co., Ltd. (KOSDAQ:084650) Stock Yet As It Plummets 26%Unfortunately for some shareholders, the LabGenomics Co., Ltd. ( KOSDAQ:084650 ) share price has dived 26% in the last...分析記事 • Nov 08Is LabGenomics (KOSDAQ:084650) Weighed On By Its Debt Load?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Sep 21Slammed 29% LabGenomics Co., Ltd. (KOSDAQ:084650) Screens Well Here But There Might Be A CatchLabGenomics Co., Ltd. ( KOSDAQ:084650 ) shares have retraced a considerable 29% in the last month, reversing a fair...New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (14% average weekly change).分析記事 • Aug 06Market Might Still Lack Some Conviction On LabGenomics Co., Ltd. (KOSDAQ:084650) Even After 35% Share Price BoostLabGenomics Co., Ltd. ( KOSDAQ:084650 ) shares have had a really impressive month, gaining 35% after a shaky period...New Risk • Aug 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 11% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.6% average weekly change).分析記事 • Jul 27Is LabGenomics (KOSDAQ:084650) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...分析記事 • Apr 09Market Still Lacking Some Conviction On LabGenomics Co., Ltd. (KOSDAQ:084650)LabGenomics Co., Ltd.'s ( KOSDAQ:084650 ) price-to-sales (or "P/S") ratio of 2.8x might make it look like a strong buy...New Risk • Mar 28New major risk - Revenue and earnings growthEarnings have declined by 1.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.Valuation Update With 7 Day Price Move • Nov 21Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₩4,050, the stock trades at a trailing P/E ratio of 72.7x. Average forward P/E is 40x in the Biotechs industry in South Korea. Total returns to shareholders of 9.9% over the past three years.Reported Earnings • Nov 19Third quarter 2023 earnings released: ₩21.00 loss per share (vs ₩232 profit in 3Q 2022)Third quarter 2023 results: ₩21.00 loss per share (down from ₩232 profit in 3Q 2022). Revenue: ₩21.2b (down 14% from 3Q 2022). Net loss: ₩1.55b (down 120% from profit in 3Q 2022). Revenue is forecast to grow 38% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Biotechs industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.Valuation Update With 7 Day Price Move • Oct 19Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩3,670, the stock trades at a trailing P/E ratio of 20.1x. Average trailing P/E is 27x in the Biotechs industry in South Korea. Total loss to shareholders of 28% over the past three years.Buying Opportunity • Sep 25Now 23% undervaluedOver the last 90 days, the stock is up 35%. The fair value is estimated to be ₩6,026, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.9% over the last 3 years. Earnings per share has grown by 4.3%.Valuation Update With 7 Day Price Move • Aug 11Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₩5,420, the stock trades at a trailing P/E ratio of 27.8x. Average trailing P/E is 32x in the Biotechs industry in South Korea. Total loss to shareholders of 9.3% over the past three years.New Risk • Aug 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Short dividend paying track record (1 year of continuous dividend payments). Share price has been volatile over the past 3 months (8.5% average weekly change). Profit margins are more than 30% lower than last year (18% net profit margin). Shareholders have been diluted in the past year (9.2% increase in shares outstanding).Valuation Update With 7 Day Price Move • Jul 24Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩9,830, the stock trades at a trailing P/E ratio of 25.2x. Average trailing P/E is 27x in the Biotechs industry in South Korea. Total loss to shareholders of 26% over the past three years.Valuation Update With 7 Day Price Move • Jul 10Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩8,200, the stock trades at a trailing P/E ratio of 21x. Average trailing P/E is 26x in the Biotechs industry in South Korea. Total loss to shareholders of 9.6% over the past three years.Valuation Update With 7 Day Price Move • Apr 05Investor sentiment improves as stock rises 24%After last week's 24% share price gain to ₩6,470, the stock trades at a trailing P/E ratio of 5x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total loss to shareholders of 5.5% over the past three years.Reported Earnings • Mar 26Full year 2022 earnings released: EPS: ₩1,429 (vs ₩2,481 in FY 2021)Full year 2022 results: EPS: ₩1,429 (down from ₩2,481 in FY 2021). Revenue: ₩144.8b (down 28% from FY 2021). Net income: ₩48.4b (down 42% from FY 2021). Profit margin: 33% (down from 41% in FY 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Mar 16Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩5,480, the stock trades at a trailing P/E ratio of 2.7x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total loss to shareholders of 3.3% over the past three years.お知らせ • Jan 19LabGenomics Co., Ltd. announced that it has received KRW 22.71198072 billion in fundingOn January 18, 2023, LabGenomics Co., Ltd. closed the transaction. The company amended the terms of the transaction. The company issued 3,128,372 shares at an issue price of KRW 7,260 per share for gross proceeds of KRW 22,711,980,720. The transaction included participation from Ruha Galacticos Co., Ltd., for 3,128,372 shares.Upcoming Dividend • Dec 21Upcoming dividend of ₩100.00 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 21 April 2023. Payout ratio is a comfortable 4.5% and this is well supported by cash flows. Trailing yield: 1.5%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (0.7%).Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Oct 04Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩6,400, the stock trades at a trailing P/E ratio of 2.4x. Average trailing P/E is 20x in the Biotechs industry in South Korea. Total returns to shareholders of 319% over the past three years.Valuation Update With 7 Day Price Move • Sep 14Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩6,910, the stock trades at a trailing P/E ratio of 2.5x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total returns to shareholders of 343% over the past three years.Valuation Update With 7 Day Price Move • Aug 25Investor sentiment deteriorated over the past weekAfter last week's 24% share price decline to ₩6,780, the stock trades at a trailing P/E ratio of 2.1x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total returns to shareholders of 369% over the past three years.Valuation Update With 7 Day Price Move • Jul 05Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩6,980, the stock trades at a trailing P/E ratio of 2.1x. Average trailing P/E is 22x in the Biotechs industry in South Korea. Total returns to shareholders of 268% over the past three years.Valuation Update With 7 Day Price Move • Apr 29Investor sentiment deteriorated over the past weekAfter last week's 23% share price decline to ₩7,090, the stock trades at a trailing P/E ratio of 2.8x. Average trailing P/E is 27x in the Biotechs industry in South Korea. Total returns to shareholders of 177% over the past three years.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Mar 16Investor sentiment improved over the past weekAfter last week's 41% share price gain to ₩31,700, the stock trades at a trailing P/E ratio of 5.5x. Average trailing P/E is 34x in the Biotechs industry in South Korea. Total returns to shareholders of 334% over the past three years.Valuation Update With 7 Day Price Move • Feb 03Investor sentiment improved over the past weekAfter last week's 24% share price gain to ₩29,400, the stock trades at a trailing P/E ratio of 5.1x. Average trailing P/E is 32x in the Biotechs industry in South Korea. Total returns to shareholders of 329% over the past three years.Valuation Update With 7 Day Price Move • Dec 23Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩25,900, the stock trades at a trailing P/E ratio of 4.5x. Average trailing P/E is 39x in the Biotechs industry in South Korea. Total returns to shareholders of 332% over the past three years.Valuation Update With 7 Day Price Move • Nov 26Investor sentiment improved over the past weekAfter last week's 33% share price gain to ₩31,400, the stock trades at a trailing P/E ratio of 7.2x. Average trailing P/E is 34x in the Biotechs industry in South Korea. Total returns to shareholders of 394% over the past three years.Valuation Update With 7 Day Price Move • Oct 06Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩24,750, the stock trades at a trailing P/E ratio of 5.7x. Average trailing P/E is 38x in the Biotechs industry in South Korea. Total returns to shareholders of 205% over the past three years.Valuation Update With 7 Day Price Move • Aug 18Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩29,250, the stock trades at a trailing P/E ratio of 6.1x. Average trailing P/E is 46x in the Biotechs industry in South Korea. Total returns to shareholders of 221% over the past three years.Valuation Update With 7 Day Price Move • Jul 28Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩34,300, the stock trades at a trailing P/E ratio of 7.1x. Average trailing P/E is 43x in the Biotechs industry in South Korea. Total returns to shareholders of 321% over the past three years.Valuation Update With 7 Day Price Move • Jul 08Investor sentiment improved over the past weekAfter last week's 30% share price gain to ₩32,550, the stock trades at a trailing P/E ratio of 6.8x. Average trailing P/E is 48x in the Biotechs industry in South Korea. Total returns to shareholders of 272% over the past three years.Valuation Update With 7 Day Price Move • May 28Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩23,350, the stock trades at a trailing P/E ratio of 6x. Average trailing P/E is 46x in the Biotechs industry in South Korea. Total returns to shareholders of 116% over the past three years.Valuation Update With 7 Day Price Move • Apr 26Investor sentiment improved over the past weekAfter last week's 23% share price gain to ₩27,600, the stock trades at a trailing P/E ratio of 7.1x. Average trailing P/E is 54x in the Biotechs industry in South Korea. Total returns to shareholders of 150% over the past three years.Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improved over the past weekAfter last week's 30% share price gain to ₩22,350, the stock trades at a trailing P/E ratio of 5.7x. Average trailing P/E is 50x in the Biotechs industry in South Korea. Total returns to shareholders of 55% over the past three years.分析記事 • Mar 31If You Like EPS Growth Then Check Out LabGenomics (KOSDAQ:084650) Before It's Too LateIt's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...Is New 90 Day High Low • Feb 22New 90-day low: ₩15,300The company is down 33% from its price of ₩22,750 on 24 November 2020. The South Korean market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period.Is New 90 Day High Low • Jan 15New 90-day low: ₩15,850The company is down 54% from its price of ₩34,550 on 16 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 22% over the same period.Is New 90 Day High Low • Dec 28New 90-day low: ₩17,500The company is down 51% from its price of ₩35,500 on 29 September 2020. The South Korean market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 15% over the same period.Is New 90 Day High Low • Dec 08New 90-day low: ₩20,600The company is down 48% from its price of ₩39,850 on 09 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 9.0% over the same period.Is New 90 Day High Low • Nov 10New 90-day low: ₩27,300The company is down 33% from its price of ₩40,800 on 12 August 2020. The South Korean market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 5.0% over the same period.Is New 90 Day High Low • Oct 22New 90-day low: ₩31,650The company is down 22% from its price of ₩40,450 on 24 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 10.0% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、LabGenomics は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測KOSDAQ:A084650 - アナリストの将来予測と過去の財務データ ( )KRW Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/202684,190-63,708-30,288-28,494N/A12/31/202588,161-64,375-32,199-30,536N/A9/30/202589,364-35,812-28,510-27,451N/A6/30/202587,971-35,040-24,316-22,270N/A3/31/202587,900-20,134-20,196-16,925N/A12/31/202485,898-23,583-17,542-12,995N/A9/30/202483,745-22,168-9,370-4,166N/A6/30/202483,275-21,007-13,787-9,844N/A3/31/202476,293-17,900-12,632-9,885N/A12/31/202371,076-4,719-9,023-3,827N/A9/30/202369,8484,13523,55929,176N/A6/30/202373,18813,55825,77531,806N/A3/31/202379,80414,48364,33572,528N/A12/31/2022144,77348,39730,62568,955N/A9/30/2022187,00974,15129,58667,149N/A6/30/2022215,95290,80049,76187,031N/A3/31/2022248,011108,70211,72658,373N/A12/31/2021202,40783,85551,54765,362N/A9/30/2021173,03964,68235,93349,661N/A6/30/2021146,33649,14828,51842,302N/A3/31/2021141,63253,80244,84147,244N/A12/31/2020119,47842,76644,85746,372N/A9/30/202097,27938,38225,10026,614N/A6/30/202078,95629,47918,52120,125N/A3/31/202038,2373,1755,8915,441N/A12/31/201933,175962N/A3,188N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: A084650の予測収益成長が 貯蓄率 ( 3.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: A084650の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: A084650の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: A084650の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: A084650の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: A084650の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/11 20:51終値2026/06/11 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋LabGenomics Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Hyung Soo KimHanwha Investment & Securities Co., Ltd.Wan KuiM SecuritiesKyung-Churl NohSK Securities Co., Ltd.1 その他のアナリストを表示
New Risk • Jun 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 70% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (₩85.9b market cap, or US$56.3m).
お知らせ • May 22LabGenomics Co., Ltd. announced that it has received KRW 20 billion in fundingOn May 20, 2026, LabGenomics Co., Ltd. has closed the transaction.
お知らせ • May 13LabGenomics Co., Ltd. announced that it expects to receive KRW 20 billion in fundingLabGenomics Co., Ltd. announces a private placement with Stick Litmus Co., Ltd. to issue Series 5 Unregistered Unsecured Private Convertible Bonds for gross proceeds of KRW 20,000,000,000 on May 12, 2026. Expected closing date of the transaction is May 20, 2026. Interest rate of the Notes is 0% and Maturity interest rate is 5%. Maturity date of the Notes is May 20, 2029. Notes are convertible into 13,642,564 shares at a conversion price of KRW 1,466. Conversion billing period starts from May 20, 2027 and ends on April 20, 2029.
お知らせ • Feb 28LabGenomics Co., Ltd., Annual General Meeting, Mar 31, 2026LabGenomics Co., Ltd., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: auditorium, 700, daewangpangyo-ro, bundang-gu, gyeonggi-do, seongnam South Korea
分析記事 • Jan 28Little Excitement Around LabGenomics Co., Ltd.'s (KOSDAQ:084650) RevenuesYou may think that with a price-to-sales (or "P/S") ratio of 1.5x LabGenomics Co., Ltd. ( KOSDAQ:084650 ) is definitely...
New Risk • Dec 15New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩141.1b (US$96.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 57% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩141.1b market cap, or US$96.4m).
分析記事 • Oct 28LabGenomics Co., Ltd.'s (KOSDAQ:084650) Price Is Right But Growth Is LackingWith a price-to-sales (or "P/S") ratio of 2.1x LabGenomics Co., Ltd. ( KOSDAQ:084650 ) may be sending very bullish...
New Risk • May 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 30% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (10% average weekly change).
分析記事 • May 19Insufficient Growth At LabGenomics Co., Ltd. (KOSDAQ:084650) Hampers Share PriceLabGenomics Co., Ltd.'s ( KOSDAQ:084650 ) price-to-sales (or "P/S") ratio of 2.2x might make it look like a strong buy...
分析記事 • Apr 08Is LabGenomics (KOSDAQ:084650) Using Debt In A Risky Way?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
お知らせ • Feb 21LabGenomics Co., Ltd., Annual General Meeting, Mar 26, 2025LabGenomics Co., Ltd., Annual General Meeting, Mar 26, 2025, at 09:00 Tokyo Standard Time. Location: auditorium, 700, daewangpangyo-ro, bundang-gu, gyeonggi-do, seongnam South Korea
New Risk • Jan 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 25% per year over the past 5 years.
分析記事 • Jan 06There's No Escaping LabGenomics Co., Ltd.'s (KOSDAQ:084650) Muted Revenues Despite A 46% Share Price RiseLabGenomics Co., Ltd. ( KOSDAQ:084650 ) shareholders would be excited to see that the share price has had a great...
分析記事 • Nov 17Not Many Are Piling Into LabGenomics Co., Ltd. (KOSDAQ:084650) Stock Yet As It Plummets 26%Unfortunately for some shareholders, the LabGenomics Co., Ltd. ( KOSDAQ:084650 ) share price has dived 26% in the last...
分析記事 • Nov 08Is LabGenomics (KOSDAQ:084650) Weighed On By Its Debt Load?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
分析記事 • Sep 21Slammed 29% LabGenomics Co., Ltd. (KOSDAQ:084650) Screens Well Here But There Might Be A CatchLabGenomics Co., Ltd. ( KOSDAQ:084650 ) shares have retraced a considerable 29% in the last month, reversing a fair...
New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (14% average weekly change).
分析記事 • Aug 06Market Might Still Lack Some Conviction On LabGenomics Co., Ltd. (KOSDAQ:084650) Even After 35% Share Price BoostLabGenomics Co., Ltd. ( KOSDAQ:084650 ) shares have had a really impressive month, gaining 35% after a shaky period...
New Risk • Aug 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 11% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.6% average weekly change).
分析記事 • Jul 27Is LabGenomics (KOSDAQ:084650) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
分析記事 • Apr 09Market Still Lacking Some Conviction On LabGenomics Co., Ltd. (KOSDAQ:084650)LabGenomics Co., Ltd.'s ( KOSDAQ:084650 ) price-to-sales (or "P/S") ratio of 2.8x might make it look like a strong buy...
New Risk • Mar 28New major risk - Revenue and earnings growthEarnings have declined by 1.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.
Valuation Update With 7 Day Price Move • Nov 21Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₩4,050, the stock trades at a trailing P/E ratio of 72.7x. Average forward P/E is 40x in the Biotechs industry in South Korea. Total returns to shareholders of 9.9% over the past three years.
Reported Earnings • Nov 19Third quarter 2023 earnings released: ₩21.00 loss per share (vs ₩232 profit in 3Q 2022)Third quarter 2023 results: ₩21.00 loss per share (down from ₩232 profit in 3Q 2022). Revenue: ₩21.2b (down 14% from 3Q 2022). Net loss: ₩1.55b (down 120% from profit in 3Q 2022). Revenue is forecast to grow 38% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Biotechs industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.
Valuation Update With 7 Day Price Move • Oct 19Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩3,670, the stock trades at a trailing P/E ratio of 20.1x. Average trailing P/E is 27x in the Biotechs industry in South Korea. Total loss to shareholders of 28% over the past three years.
Buying Opportunity • Sep 25Now 23% undervaluedOver the last 90 days, the stock is up 35%. The fair value is estimated to be ₩6,026, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.9% over the last 3 years. Earnings per share has grown by 4.3%.
Valuation Update With 7 Day Price Move • Aug 11Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₩5,420, the stock trades at a trailing P/E ratio of 27.8x. Average trailing P/E is 32x in the Biotechs industry in South Korea. Total loss to shareholders of 9.3% over the past three years.
New Risk • Aug 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Short dividend paying track record (1 year of continuous dividend payments). Share price has been volatile over the past 3 months (8.5% average weekly change). Profit margins are more than 30% lower than last year (18% net profit margin). Shareholders have been diluted in the past year (9.2% increase in shares outstanding).
Valuation Update With 7 Day Price Move • Jul 24Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩9,830, the stock trades at a trailing P/E ratio of 25.2x. Average trailing P/E is 27x in the Biotechs industry in South Korea. Total loss to shareholders of 26% over the past three years.
Valuation Update With 7 Day Price Move • Jul 10Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩8,200, the stock trades at a trailing P/E ratio of 21x. Average trailing P/E is 26x in the Biotechs industry in South Korea. Total loss to shareholders of 9.6% over the past three years.
Valuation Update With 7 Day Price Move • Apr 05Investor sentiment improves as stock rises 24%After last week's 24% share price gain to ₩6,470, the stock trades at a trailing P/E ratio of 5x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total loss to shareholders of 5.5% over the past three years.
Reported Earnings • Mar 26Full year 2022 earnings released: EPS: ₩1,429 (vs ₩2,481 in FY 2021)Full year 2022 results: EPS: ₩1,429 (down from ₩2,481 in FY 2021). Revenue: ₩144.8b (down 28% from FY 2021). Net income: ₩48.4b (down 42% from FY 2021). Profit margin: 33% (down from 41% in FY 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Mar 16Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩5,480, the stock trades at a trailing P/E ratio of 2.7x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total loss to shareholders of 3.3% over the past three years.
お知らせ • Jan 19LabGenomics Co., Ltd. announced that it has received KRW 22.71198072 billion in fundingOn January 18, 2023, LabGenomics Co., Ltd. closed the transaction. The company amended the terms of the transaction. The company issued 3,128,372 shares at an issue price of KRW 7,260 per share for gross proceeds of KRW 22,711,980,720. The transaction included participation from Ruha Galacticos Co., Ltd., for 3,128,372 shares.
Upcoming Dividend • Dec 21Upcoming dividend of ₩100.00 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 21 April 2023. Payout ratio is a comfortable 4.5% and this is well supported by cash flows. Trailing yield: 1.5%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (0.7%).
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Oct 04Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩6,400, the stock trades at a trailing P/E ratio of 2.4x. Average trailing P/E is 20x in the Biotechs industry in South Korea. Total returns to shareholders of 319% over the past three years.
Valuation Update With 7 Day Price Move • Sep 14Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩6,910, the stock trades at a trailing P/E ratio of 2.5x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total returns to shareholders of 343% over the past three years.
Valuation Update With 7 Day Price Move • Aug 25Investor sentiment deteriorated over the past weekAfter last week's 24% share price decline to ₩6,780, the stock trades at a trailing P/E ratio of 2.1x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total returns to shareholders of 369% over the past three years.
Valuation Update With 7 Day Price Move • Jul 05Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩6,980, the stock trades at a trailing P/E ratio of 2.1x. Average trailing P/E is 22x in the Biotechs industry in South Korea. Total returns to shareholders of 268% over the past three years.
Valuation Update With 7 Day Price Move • Apr 29Investor sentiment deteriorated over the past weekAfter last week's 23% share price decline to ₩7,090, the stock trades at a trailing P/E ratio of 2.8x. Average trailing P/E is 27x in the Biotechs industry in South Korea. Total returns to shareholders of 177% over the past three years.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Mar 16Investor sentiment improved over the past weekAfter last week's 41% share price gain to ₩31,700, the stock trades at a trailing P/E ratio of 5.5x. Average trailing P/E is 34x in the Biotechs industry in South Korea. Total returns to shareholders of 334% over the past three years.
Valuation Update With 7 Day Price Move • Feb 03Investor sentiment improved over the past weekAfter last week's 24% share price gain to ₩29,400, the stock trades at a trailing P/E ratio of 5.1x. Average trailing P/E is 32x in the Biotechs industry in South Korea. Total returns to shareholders of 329% over the past three years.
Valuation Update With 7 Day Price Move • Dec 23Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩25,900, the stock trades at a trailing P/E ratio of 4.5x. Average trailing P/E is 39x in the Biotechs industry in South Korea. Total returns to shareholders of 332% over the past three years.
Valuation Update With 7 Day Price Move • Nov 26Investor sentiment improved over the past weekAfter last week's 33% share price gain to ₩31,400, the stock trades at a trailing P/E ratio of 7.2x. Average trailing P/E is 34x in the Biotechs industry in South Korea. Total returns to shareholders of 394% over the past three years.
Valuation Update With 7 Day Price Move • Oct 06Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩24,750, the stock trades at a trailing P/E ratio of 5.7x. Average trailing P/E is 38x in the Biotechs industry in South Korea. Total returns to shareholders of 205% over the past three years.
Valuation Update With 7 Day Price Move • Aug 18Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩29,250, the stock trades at a trailing P/E ratio of 6.1x. Average trailing P/E is 46x in the Biotechs industry in South Korea. Total returns to shareholders of 221% over the past three years.
Valuation Update With 7 Day Price Move • Jul 28Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩34,300, the stock trades at a trailing P/E ratio of 7.1x. Average trailing P/E is 43x in the Biotechs industry in South Korea. Total returns to shareholders of 321% over the past three years.
Valuation Update With 7 Day Price Move • Jul 08Investor sentiment improved over the past weekAfter last week's 30% share price gain to ₩32,550, the stock trades at a trailing P/E ratio of 6.8x. Average trailing P/E is 48x in the Biotechs industry in South Korea. Total returns to shareholders of 272% over the past three years.
Valuation Update With 7 Day Price Move • May 28Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩23,350, the stock trades at a trailing P/E ratio of 6x. Average trailing P/E is 46x in the Biotechs industry in South Korea. Total returns to shareholders of 116% over the past three years.
Valuation Update With 7 Day Price Move • Apr 26Investor sentiment improved over the past weekAfter last week's 23% share price gain to ₩27,600, the stock trades at a trailing P/E ratio of 7.1x. Average trailing P/E is 54x in the Biotechs industry in South Korea. Total returns to shareholders of 150% over the past three years.
Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improved over the past weekAfter last week's 30% share price gain to ₩22,350, the stock trades at a trailing P/E ratio of 5.7x. Average trailing P/E is 50x in the Biotechs industry in South Korea. Total returns to shareholders of 55% over the past three years.
分析記事 • Mar 31If You Like EPS Growth Then Check Out LabGenomics (KOSDAQ:084650) Before It's Too LateIt's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
Is New 90 Day High Low • Feb 22New 90-day low: ₩15,300The company is down 33% from its price of ₩22,750 on 24 November 2020. The South Korean market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period.
Is New 90 Day High Low • Jan 15New 90-day low: ₩15,850The company is down 54% from its price of ₩34,550 on 16 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 22% over the same period.
Is New 90 Day High Low • Dec 28New 90-day low: ₩17,500The company is down 51% from its price of ₩35,500 on 29 September 2020. The South Korean market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 15% over the same period.
Is New 90 Day High Low • Dec 08New 90-day low: ₩20,600The company is down 48% from its price of ₩39,850 on 09 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 9.0% over the same period.
Is New 90 Day High Low • Nov 10New 90-day low: ₩27,300The company is down 33% from its price of ₩40,800 on 12 August 2020. The South Korean market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 5.0% over the same period.
Is New 90 Day High Low • Oct 22New 90-day low: ₩31,650The company is down 22% from its price of ₩40,450 on 24 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 10.0% over the same period.